Trending NewsTrending NewsNASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $110.79 +1.07 (+0.98%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$111.20 +0.40 (+0.37%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Halozyme Therapeutics Stock (NASDAQ:HALO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$110.16▼$114.0050-Day Range$82.27▼$115.2252-Week Range$61.22▼$116.85Volume2.18 million shsAverage Volume2.60 million shsMarket Capitalization$12.57 billionP/E Ratio33.07Dividend YieldN/APrice Target$91.20Consensus RatingModerate Buy Company Overview Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection. Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies. Products using the company’s technology include subcutaneous formulations of several commercially available treatments, such as DARZALEX FASPRO, PHESGO, VYVGART HYTRULO and HyQvia. Halozyme also markets HYLENEX recombinant, a standalone hyaluronidase product used to facilitate the absorption and dispersion of other injected medicines and fluids. Founded in 1998 and headquartered in San Diego, California, Halozyme serves international markets primarily through licensing, collaboration and commercialization agreements with healthcare companies. Its business model combines technology partnerships, milestone payments and royalties tied to products that use its drug-delivery platforms.AI Generated. May Contain Errors. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 326th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.Downside RiskHalozyme Therapeutics has a consensus price target of $91.20, representing about 17.7% downside from its current price of $110.79.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth13.09% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 13.09% in the coming year, from $8.25 to $9.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 33.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 33.07, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.56.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 263.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.69% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 11.59, which indicates bearish sentiment.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 1.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.49 News SentimentHalozyme Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.Search Interest13 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,311,844.00 in company stock.Percentage Held by Insiders2.50% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Stock News HeadlinesHalozyme Granted Another Injunction Against Merck in Keytruda Patent CaseOctober 7 at 5:38 PM | marketwatch.comHalozyme Wins Injunction Against Merck in Keytruda Patent Case -- UpdateOctober 7 at 5:38 PM | marketwatch.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production. | Golden Portfolio (Ad)Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?October 7 at 5:38 PM | finance.yahoo.comHalozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsOctober 7 at 8:30 AM | prnewswire.comHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive ...October 7 at 7:36 AM | finance.yahoo.comHalozyme Therapeutics (NASDAQ:HALO) Director Sells 5,230 Shares of StockOctober 3, 2026 | insidertrades.comHalozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of StockSeptember 12, 2026 | insidertrades.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $67.30 at the beginning of the year. Since then, HALO stock has increased by 64.6% and is now trading at $110.79. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm's revenue was up 47.7% compared to the same quarter last year. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' top institutional investors include Congress Asset Management Co. (2.01%), Juncture Wealth Strategies LLC (0.01%), MRA Advisory Group (0.01%) and Collective Family Office LLC (0.01%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2026Today10/07/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HALO's financial health is in the Green zone, according to TradeSmith. HALO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees423Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$91.20 High Price Target$115.00 Low Price Target$56.00 Potential Upside/Downside-17.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$3.35 Trailing P/E Ratio33.07 Forward P/E Ratio13.43 P/E Growth0.42Net Income$316.89 million Net Margins24.86% Pretax Margin35.06% Return on Equity260.98% Return on Assets23.91% Debt Debt-to-Equity Ratio13.50 Current Ratio2.71 Quick Ratio2.31 Sales & Book Value Annual Sales$1.40 billion Price / Sales9.00 Cash Flow$4.82 per share Price / Cash Flow23.00 Book Value$0.42 per share Price / Book263.79Miscellaneous Outstanding Shares113,500,000Free Float110,661,000Market Cap$12.57 billion OptionableOptionable Beta0.88 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:HALO) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...International Living | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
